Last reviewed · How we verify
NCT04714723
Lifestyle Intervention Trial in High Metabolic Risk Chinese
NA trial testing Programmed smartphone intervention in Metabolic Syndrome in 395 participants. Completed in 31 December 2023.
30 November 2021
Quick facts
| Lead sponsor | Chinese Academy of Sciences |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 395 |
| Start date | 27 December 2020 |
| Primary completion | 30 November 2021 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Programmed smartphone intervention
- Programmed smartphone plus dietitian intervention
Conditions studied
- Metabolic Syndrome — all drugs for Metabolic Syndrome →
- Obesity — all drugs for Obesity →
Sponsor
Chinese Academy of Sciences — full company profile →
Who can join
Adults 20 to 65, any sex, with Metabolic Syndrome or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this single-blind, randomized trial, 395 eligible volunteers, who have higher metabolic syndrome (MetS) risk and aged 20-65 years, will be assigned to one of two smartphone-based lifestyle intervention arms: 1) Programmed-smartphone intervention or 2) Programmed-smartphone plus dietitian intervention. Before and after 6-month intervention, "PhenFlex test" (PFT) was performed to examine and quantify improved metabolic flexibility. This intervention trial will be conducted by researchers in Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences (CAS) collaborating with Zhejiang University affiliated Sir Run Run Shaw Hospital. The study protocol was approved by the Ethics Committees in Shanghai Institutes of Nutrition and Health, and in Sir Run Run Shaw Hospital. The main aims of this study are to determine 1) efficacy of lifestyle interventions with different intensity in reducing MetS and its risk factors; 2) improved metabolic responses or flexibility defined by PFT-based homeostasis index; and 3) major genetic and nongenetic determinants for the efficacy of interventions among high MetS risk Chinese.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impacts of Behavioral Compliance on Weight-Loss and Metabolic Profile in a Smartphone App-Based Lifestyle Intervention or Plus Dietitian Supporting: A Randomized and Controlled Trial Among Chinese.
Li X, Lu L, Sun L, Xie Y, et al · · 2025 · cited 1× · PMID 40606567 · DOI 10.1007/s43657-024-00162-0
Verify or expand the search:
- PubMed search for NCT04714723
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Syndrome
Currently open trials in the same condition.
- NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
- NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
- NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
Other Chinese Academy of Sciences trials
Trials by the same sponsor.
- NCT07170345 — Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion · recruiting
- NCT07158372 — Research on Identifying Critical Surgical Anatomy in Cholecystectomy Videos Based on Deep Learning · recruiting
- NCT06989177 — Probiotic Intervention on Body Weight · NA · recruiting
- NCT06989203 — Protein Supplementation Intervention on Body Weight · NA · recruiting
- NCT06035250 — AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04714723 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Sciences
- Last refreshed: 9 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04714723.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing